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Methemoglobinemia: An unusual cause of
postoperative cyanosis
Carryn M. Anderson, MD, Kenneth J. Woodside, MD, Todd A. Spencer, MD, and Glenn C. Hunter,
MD, Galveston, Tex
Methemoglobinemia, although rare, must be considered in surgical patients presenting with acute respiratory distress and
cyanosis. We report two cases of methemoglobinemia in patients undergoing aortic reconstruction. The first patient
developed methemoglobinemia while on a nitroglycerin infusion, and the second after receiving benzocaine spray before
intubation. Both patients were treated with methylene blue and ascorbic acid, with resolution of their hypoxia and
cyanosis. The pathophysiology, etiology, diagnosis, and treatment of methemoglobinemia are reviewed. (J Vasc Surg
2004;39:686-90.)
Methemoglobin (MHb) is formed when the ferrous
(Fe2) iron moiety of hemoglobin is oxidized to the ferric
(Fe3) state. Excess MHb leads to cyanosis, impaired aer-
obic respiration, metabolic acidosis, and in severe cases,
death. The most common etiology of methemoglobinemia
is ingestion or skin exposure to oxidizing agents.1 Other
etiologies include genetic deficiencies of cytochrome-b5
and cytochrome-b5 reductase, dietary ingestion of nitrates
in well water, and idiopathic causes.2,3 As a life-threatening
condition, methemoglobinemia must be recognized early
and treatment initiated promptly. Unfortunately, pulse
oximetry and arterial blood gases can be misleading in
patients with methemoglobinemia.4-7 Co-oximetry is the
most accurate way of measuring the MHb level and of
diagnosing the disorder.8 We have recently managed two
patients who developed acute respiratory distress and cya-
nosis following aortobifemoral bypass grafting procedures.
In this report, we review the pathophysiology, etiology,
diagnosis, and treatment of methemoglobinemia in these
two critically ill patients.
CASE REPORT
Case 1. The patient was a 57-year-old Caucasian female with
a history of hypertension, coronary artery disease, myocardial
infarction, paroxysmal atrial fibrillation, and chronic obstructive
pulmonary disease. After preoperative evaluation, she was admitted
for an aortobifemoral bypass for bilateral lower-extremity rest pain.
Her outpatient medications included clonidine, verapamil, couma-
din, nitroglycerin, amlodipine, digoxin, hydrochlorothiazide, and
diazepam.
Aortobifemoral bypass grafting was performed without major
complications. The patient remained intubated and was transferred
to the surgical intensive care unit. Postoperatively, she received
fenoldopam, nitroglycerin (0.25 mcg/kg per min), metoprolol,
and two units of packed red blood cells. The next morning, she was
extubated uneventfully.
On the second postoperative day, the patient’s pulse oximetry
value fell to 90% despite being on 50% oxygen by aerosol face mask.
On physical examination, she had labored breathing, with a respi-
ratory rate of 20 breaths per minute and diminished air entry
bilaterally. After two albuterol and ipratropium nebulizer treat-
ments, her dyspnea resolved and her oxygen (O2) saturation im-
proved to 95%, with improvement in breath sounds in both
lungs.
Four hours later, the patient was noted to be lethargic, with
confused speech. Her pulse rate was 119 beats per minute and her
blood pressure 118/65 mm Hg. Her respirations were labored,
with accessory muscle recruitment. Coarse rales with rhonchi were
noted on auscultation. Pulse oximetry showed O2 saturation of
88%. The patient was placed on a nonrebreather face mask at 100%
O2. Initially, the O2 saturation increased to 98%, then decreased to
94% with the development of cyanosis. Because of her labored
breathing and decreased O2 saturation, the patient was intubated.
Despite an O2 saturation of 95%, her cyanosis continued to in-
crease. When arterial blood gas samples were obtained, it was
noted that the blood was chocolate brown in color (Fig 1).
Methemoglobin levels were ordered and co-oximetry revealed
MHb level of 31.0%.
The nitroglycerin infusion (0.25 mcg/kg per min) was discon-
tinued after a total dose of 50 mg. A single dose of methylene blue
(2 mg/kg) was infused intravenously over 5 minutes, and 2 gm of
ascorbic acid was given intravenously piggyback. Arterial blood
gases and MHb levels were redrawn 30 minutes after administra-
tion of the methylene blue (Table I). Over the next 24 hours, the
patient’s cyanosis, tachypnea, and tachycardia resolved as her MHb
level returned to within the normal range (0.4%-1.5%). She was
later extubated uneventfully.
Case 2. The patient, a 73-year-old Caucasian female with a
history of hypertension, diabetes mellitus, osteoarthritis, and con-
gestive heart failure, underwent an aortobifemoral bypass with
bilateral common femoral artery endarterectomies for infrarenal
aortic occlusion. The patient’s postoperative course was compli-
cated by a hemothorax after central line placement, requiring
thoracotomy 18 days after the bypass procedure. Four days after
the thoracotomy, the patient was extubated.
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One hour later, the patient became tachypneic and dyspneic,
with an oxygen saturation of 95% on 100% O2 nonrebreather face
mask. She was given a nebulizer treatment of albuterol and ipra-
tropium and placed on bilevel positive airway pressure, with im-
provement in her dyspnea and anxiety. Later that morning, the
patient was again tachypneic and tachycardic, but now with cyano-
sis and a pulse oximetry value of 65%. A blood gas was drawn and
processed on a co-oximeter, showing a PaO2 of 30 mm Hg and
MHb level of 0.5%. Immediately before reintubation, the patient
was given two oropharyngeal sprays of benzocaine. She was placed
on synchronized intermittent mandatory ventilation at a rate of 10
breaths per minute, and FiO2 of 1.0. O2 saturation was increased
to 98%.
An hour later, the patient developed peripheral and central
cyanosis associated with tachypnea and tachycardia. Another arte-
rial blood gas was drawn and processed on a co-oximeter, revealing
a PaO2 of 322 mm Hg and an MHb level of 43.7%. The patient was
somnolent, but able to follow commands. She was given single
doses of methylene blue (2 mg/kg, infused over 5 min) and
ascorbic acid (2 gm, intravenously piggyback) intravenously.
Within 30 minutes, her MHb level had decreased to 27.1%. She
was given a repeat intravenous dose of methylene blue and ascorbic
acid. O2 saturation was 94% at that time, and the patient’s respira-
tions and heart rate had appropriately decreased. Within 2 hours of
the first dose of methylene blue, the MHb level fell to 5.1%. The
patient’s cyanosis resolved and she was later extubated unevent-
fully.
DISCUSSION
When the ferrous (Fe2) iron moiety of hemoglobin is
oxidized to the ferric (Fe3) state to form MHb, hemoglo-
bin loses its ability to transport molecular oxygen and
carbon dioxide. Excess MHb leads to cyanosis, impaired
aerobic respiration, metabolic acidosis, and in severe cases,
death. Cytochrome-b5-MHb reductase, reduced NADPH-
MHb reductase, and reduced glutathione within erythro-
cytes function as antioxidants to convert MHb back to
hemoglobin (Fig 2).1 Methemoglobinemia becomes life
threatening when these enzyme systems become over-
whelmed.
Fig 2. Reduction of methemoglobin to hemoglobin. (From
Wright OR, Lewander WJ, Woolf AD. Methemoglobinemia: eti-
ology, pharmacology, and clinical management. Ann Emerg Med
1999;34:646-56. By permission).
Fig 1. An arterial blood sample from our first patient at 12.7%
MHb (left) and 31.0% MHb (right). Notice the dark brown hue of
the sample with the higher MHb level.
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As the MHb concentration increases, patients become
cyanotic, as evidenced in our two patients. Anxiety, light-
headedness, headache, and tachycardia, followed by confu-
sion and tachypnea, are the usual symptoms. As the MHb
level rises, patients may develop acidosis, seizures, arrhyth-
mias, and eventually coma and death (Table II). Patients
with underlying cardiac, pulmonary, or hematologic dis-
ease may experience more severe symptoms for a given
MHb concentration.1 In our patients, it is likely that anxi-
ety, agitation, tachycardia, lethargy, confusion, hypoxia,
and cyanosis were symptoms of worsening methemoglo-
binemia. Both patients had underlying cardiac and pulmo-
nary disease that could have worsened their symptoms in
response to high MHb levels.
The most common etiology of methemoglobinemia in
adults is ingestion or skin exposure to oxidizing agents.
There is a growing list of medications that have been found
to produce methemoglobinemia (Table III). Common
agents include aniline dyes, benzocaine, dapsone, nitrates,
nitrites, and naphthalene. It appears likely that our first
patient formed MHb in response to intravenous nitroglyc-
erin, which was possibly exacerbated by using benzocaine
spray before her intubation. The total dose of nitroglycerin
that the patient received was 50 mg, which is a reasonable
dose to treat hypertension. Although it is possible that
there was a pharmacy error or a variation in infusion rate,
this could not be substantiated from the medical record.
Kaplan et al2 have shown that the dose and rate of infusion
of nitroglycerin are significant factors in the development of
methemoglobinemia. Patient age, weight, renal and he-
patic function, and arterial oxygen saturation are additional
confounding variables. Because multiple factors contribute
to the risk of developing methemoglobinemia (ie, anemia,
pulmonary and cardiac disease, peripheral vascular disease,
shock, sepsis, acidosis, and genetics), the exact dose and
rate of nitroglycerin necessary to cause methemoglobin-
emia remain poorly defined.3
In our second patient, the methemoglobinemia
seemed temporally related to the benzocaine spray used
before intubation and may have been exacerbated by her
concurrent respiratory distress, as was the case in our first
patient. It is difficult to determine the critical dose of
benzocaine spray necessary to cause methemoglobinemia
because the administered dose is usually so variable. The
dose of drug delivered depends on the number of sprays
and on the length of each spray. Complicating the issue is
the practice of concomitantly administering varying doses
of 2% viscous lidocaine. Lidocaine was not used in either of
our patients and, therefore, could not be implicated in the
development of methemoglobinemia. Novaro et al,4 in a
review of the incidence of benzocaine-induced methemo-
globinemia in an echocardiography laboratory, found that
the degree of mucosal damage plays a role in the systemic
absorption of benzocaine and, as a consequence, the devel-
opment of methemoglobinemia. Breakdown of oropharyn-
geal, esophageal, or gastric mucosa can contribute to in-
creased absorption, as does exposure of the drug to the
tracheobronchial tree. Mucosal damage secondary to her
prior intubation may have contributed to the development
of methemoglobinemia in the second patient.
Other etiologies of methemoglobinemia include ge-
netic predisposition, dietary ingestion of nitrates, and idio-
pathic sources (most often seen in infants with severe
metabolic acidosis). Genetic deficiencies in cytochrome-b5
reductase and cytochrome-b5 result in moderately elevated
MHb levels that are generally well tolerated.5 Neither of
our patients had a known deficiency of either cyto-
chrome-b5 or cytochrome-b5 reductase. Dietary ingestion
of nitrates in well water may also cause methemoglobin-
emia.3 This presentation is most common in young infants
who live in rural areas where the water source may be
contaminated by fertilizer runoff. Intestinal bacteria con-
vert the nitrates to nitrites, which are potent MHb-forming
agents. Neither of our patients had drunk well water, and
they were not exposed to fertilizers before their hospital-
izations. Finally, MHb formation may be idiopathic, espe-
cially in young infants (6 months of age) who have severe











pH 7.35-7.45 7.18 7.31 7.36 7.30 7.30
PCO2 (mm Hg) 35-45 52 36 34 40 42
PO2 (mm Hg) 80-100 236 284 280 160 64
HCO3 (meq/L) 22-26 19 18 19 19 20
%MHb 0.4-1.5 31.0 23.6 12.7 5.5 2.0
MB, Methylene blue.
Table II. Correlation of clinical signs and symptoms
associated with %MHb blood levels
%MHb Clinical signs and symptoms*
10 None
10-20 Cyanosis
20-30 Anxiety, headache, lightheadedness,
tachycardia
30-50 Fatigue, dizziness, confusion,
tachypnea, increased tachycardia
50-70 Arrhythmias, acidosis, coma, seizures
70 Death
*Symptoms may be more severe for a given %MHb in patients with anemia
or underlying cardiac and pulmonary disease.
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metabolic acidosis from diarrhea and dehydration. Iatro-
genic causes (ie, same unit, same shift, pharmacy error) for
the development of methemoglobinemia in these patients
are unlikely as they occurred over a year apart.
Evaluation of cyanosis in Intensive Care Unit pa-
tients. When assessing a cyanotic patient in the intensive
care unit, two of the first diagnostic measures usually taken
include pulse oximetry and arterial blood gases. Unfortu-
nately, in the case of methemoglobinemia, the results of
these tests can be misleading. Pulse oximetry can give the
clinician a false sense of security despite the presence of
increasing methemoglobin levels. The reason for this di-
lemma stems from the technique used to determine O2
saturation in pulse oximetry. A pulse oximeter gauges light
absorbance at two wavelengths: 660 and 940 nm.9,10 O2
saturation is determined by the ratio of absorbance at these
two wavelengths (660 and 940 nm). MHb absorbs light
almost equally at both 660 and 940 nm. Therefore, at 100%
MHb in the blood, the absorbance ratio is approximately
1.0, which corresponds to an 85% O2 saturation reading by
pulse oximetry. In reality, when MHb levels reach 30% to
35%, the light absorbance reaches a plateau and the pulse
oximeter reading becomes stable in the 82% to 86% range,
regardless of rising MHb levels.9,10 As a consequence, pulse
oximetry is a poor indicator of the actual percentage of
MHb in the blood and of tissue oxygenation in patients
with methemoglobinemia.
Arterial blood gas values can also be misleading. The
arterial Po2 is a measure of dissolved oxygen and does not
directly correlate with oxygen molecules bound to hemo-
globin. This explains why patients with life-threatening
methemoglobinemia may have normal Po2 values. The
hemoglobin O2 saturation level may be unreliable, as an
arterial blood gas analyzer calculates this level from the pH
and Pco2 values, using the Henderson-Hasselbach equa-
tion for serum bicarbonate and standardized oxygen-he-
moglobin dissociation curves.7,8 This calculation assumes
the presence of normal hemoglobin. The presence of MHb
shifts the oxygen-hemoglobin dissociation curve to the left,
resulting in false elevations of the O2 saturation levels
calculated by the arterial blood gas analyzer. Co-oximetry,
which measures light absorbance at four different wave-
lengths, using spectrophotometry, is the most accurate way
of measuring MHb levels. Each of the four wavelengths
corresponds to absorbance characteristics of deoxyhemo-
globin, oxyhemoglobin, carboxyhemoglobin, and hemo-
globin.11 A peak absorbance of light at 630 nm character-
izes MHb. Combined co-oximetry and blood gas analysis
machines measure oxygen saturation values based on all
four types of hemoglobin and, therefore, are more accurate.
It is important to specifically request a MHb level so that
the blood may be processed in a co-oximeter, as MHb
levels are not routinely performed on arterial blood gas
analyzers.
Two bedside tests can be used to diagnose methemo-
globinemia. The first test distinguishes between MHb and
deoxyhemoglobin. Blood that is saturated with MHb ap-
pears chocolate brown, whereas deoxyhemoglobin appears
dark red to violet. The test involves placing one to two
drops of the patient’s blood on a piece of white filter paper.
When exposed to oxygen, deoxyhemoglobin will brighten
in color whereas MHb will remain chocolate brown. Blow-
ing 100% oxygen over the sample will speed up the reac-
tion. The second bedside test distinguishes between sulf-
hemoglobin and MHb. MHb reacts with cyanide to form
cyanomethemoglobin, a bright-red compound. Sulfhemo-
globin, which has a similar chocolate-brown appearance,
does not react with cyanide. The addition of potassium
cyanide (Drabkin’s reagent) turns MHb bright red but
does not alter sulfhemoglobin.12
Management When the diagnosis of symptomatic
methemoglobinemia is made, an infusion of methylene
blue should be initiated immediately. Methylene blue is
usually provided as a 1% solution (10 mg/mL), and 1 to 2
mg/kg (0.2 mL/kg of a 1% solution) should be infused
intravenously over a 3- to 5-minute interval. An additional
dose of 1 mg/kg may be repeated after 30 minutes if the
methemoglobinemia does not resolve.1 Methylene blue
should reduce the MHb levels significantly within an hour.
Table III. Common drugs or toxins that can cause methemoglobinemia
Acetanilid Dinitrophenol Paraquat
Alloxan Exhaust fumes Phenacetin
Aniline (dyes, ink) Ferricyanide Phenazopyridine HCl
Arsine Flutamide Phenol
Benzene derivatives Hydroxylamine Phenytoin
Benzocaine Lidocaine hydrochloride Prilocaine
Bivalent copper Metoclopramide Primaquine
Bismuth subnitrate Methylene blue Rifampin
Bupivacaine hydrochloride Naphthalene Silver nitrate
Chlorates Nitrates Sodium valproate




Dimethyl sulfoxide Sodium nitroprusside
Modified from Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: Etiology, pharmacology, and clinical management. Ann Emerg Med 1999;34:
646-56; and from Rehman HU. Methemoglobinemia. West J Med 2001;175:193-6.
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Our patients were also given 2 gm of ascorbic acid as an
additional antioxidant.13,14
An infusion of dextrose may be used in conjunction
with methylene blue, as it up-regulates the glycolytic cy-
cle—a major source of NADH in erythrocytes (Fig 2).
Dextrose is also necessary to form NADPH via the pentose
phosphate pathway. Methylene blue interacts with
NADPH to form leukomethylene blue, which converts
MHb back to hemoglobin.1,15 Wright et al1 suggest that
maintenance amounts of dextrose should be provided for
normoglycemic patients and that standard dextrose therapy
should be administered to hypoglycemic patients. Olson
and McEvoy16 gave methylene blue, 80 mg as a 1% solution
in 5% dextrose in water, infused over 20 minutes, after their
patient developed methemoglobinemia in response to top-
ical local anesthetic. We did not administer dextrose to
either of our patients, as the benefits of its routine use have
not been established.
The patient should be monitored for complications of
methylene blue therapy. Paradoxically, excessive doses of
methylene blue may cause methemoglobinemia if it is not
converted to leukomethylene blue at an adequate rate.
Patients with glucose-6-phosphate dehydrogenase defi-
ciency are at particular risk for both a suboptimal response
to methylene blue and an overdose, as they cannot produce
sufficient NADPH. Finally, patients with methemoglobin-
emia caused by drugs such as dapsone, benzocaine, and
aniline dyes may initially respond to methylene blue therapy
and then experience rebound methemoglobinemia 4 to 12
hours later.14,17 We did not observe this rebound effect in
our second patient, in whom the methemoglobinemia was
temporally related to benzocaine administration.
Methemoglobinemia, although rare, should be in-
cluded in the differential diagnosis of cyanosis with respira-
tory distress, especially in critically ill patients with known
exposure to oxidizing agents such as nitroglycerin and
benzocaine. It is a potentially life-threatening condition
that can be diagnosed by using bedside tests and co-
oximetry. Treatment with methylene blue and adjuvants
such as dextrose and ascorbic acid should be initiated
promptly.
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